

Regional Webinar on

Transition to HPV DNA test as a primary screening test for cervical cancer elimination to achieve the 2030 interim targets

Date: 29 October 2021

Time: 12:30 to 14:40 hrs (IST)

Please click the link below to join the webinar:

<https://who.zoom.us/j/92822686730>

Password: HPV@2921

Join by SIP

92822686730@zoomcrc.com

Password: 12031062



Topics

1. Welcome and introductory remarks
2. Introducing and scaling up testing for human papilloma virus as part of a comprehensive programme for prevention and control of cervical cancer
3. Overview of screening programme in SEAR
4. Country experience of transitioning from Pap smear to HPV DNA based testing including implication on costing
5. Country experience of pilot testing of HPV DNA testing and plans of moving from PAP smear to HPV DNA
6. Innovative purchasing options for HPV DNA tests and equipment for management of precancerous lesions
7. Options of integration of HPV testing into existing laboratory platforms with successful examples
8. Discussions/clarifications and closing

Speakers

Dr Neena Raina

Senior Adviser, Reproductive, Maternal, Newborn, Child & Adolescent Health and Ageing (MCA) WHO Regional Office for South-East Asia, New Delhi

Dr Nathalie Broutet

Medical Officer, Reproductive Health and Research, WHO HQ, Geneva

Dr Anoma Jayathilaka

Medical Officer, Maternal and Reproductive Health (MRH) WHO, Regional Office for South-East Asia, New Delhi

Dr Suleeporn Sangrajrang

Deputy Director, Health System Development
National Cancer Institute of Thailand

Dr Padmaka Silva

Consultant Community Physician
Family Health Bureau
Ministry of Health, Sri Lanka

Mr. Parth Bahuguna

Global Director: Cancer Cervix
Clinton Health Access Initiative (CHAI)

Mr. Owen Demke

Senior Program Manager, Global Diagnostics
Clinton Health Access Initiative (CHAI)

Ms. Anita Sands

Technical Officer, Incidents and Substandard/Falsified Medical Products Team (ISF)
WHO HQ, Geneva